KRAS and familial pancreatic carcinoma: In line with this, the SLC7A5 inhibitor JPH203 exhibited synergistic effects when combined with a KRAS G12D inhibitor in 3 pancreatic cancer cell lines carrying the KRAS G12D mutation.